Last reviewed · How we verify

Janumet, Lantus

Chinese University of Hong Kong · FDA-approved active Small molecule

Janumet combines sitagliptin (a DPP-4 inhibitor) with metformin to lower blood glucose by increasing incretin levels and reducing hepatic glucose production, while Lantus is a long-acting basal insulin that provides steady glucose control.

Janumet combines sitagliptin (a DPP-4 inhibitor) with metformin to lower blood glucose by increasing incretin levels and reducing hepatic glucose production, while Lantus is a long-acting basal insulin that provides steady glucose control. Used for Type 2 diabetes mellitus (Janumet as oral agent; Lantus as basal insulin therapy).

At a glance

Generic nameJanumet, Lantus
SponsorChinese University of Hong Kong
Drug classDPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus)
TargetDPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Janumet works through dual action: sitagliptin inhibits dipeptidyl peptidase-4 to prolong GLP-1 and GIP activity, stimulating insulin secretion in response to meals, while metformin decreases hepatic glucose output and improves insulin sensitivity. Lantus (insulin glargine) is a basal insulin analog that provides continuous glucose-lowering effect over 24 hours by mimicking the body's natural background insulin secretion. Together, these agents address multiple pathways in type 2 diabetes pathophysiology.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: